Rodrigo Fresco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/163675/publications.pdf

Version: 2024-02-01

1937685 1588992 11 452 4 8 citations h-index g-index papers 11 11 11 884 docs citations times ranked citing authors all docs

| # | Article | lF | CITATIONS |
|----|--|------|-----------|
| 1 | Planning cancer control in Latin America and the Caribbean. Lancet Oncology, The, 2013, 14, 391-436. | 10.7 | 394 |
| 2 | Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC) Journal of Clinical Oncology, 2020, 38, 1014-1014. | 1.6 | 25 |
| 3 | EPIDEMIOLOGY AND TREATMENT OF MONTEGGIA LESION IN ADULTS: SERIES OF 44 CASES. Acta Ortopedica Brasileira, 2016, 24, 48-51. | 0.5 | 20 |
| 4 | Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials. Oncologist, 2015, 20, 702-712. | 3.7 | 6 |
| 5 | Synchronous Presentation of an Askin Tumor and a Plasmacytoma in an Adult Patient. Tumori, 2003, 89, 324-327. | 1.1 | 2 |
| 6 | Reply to H.J. Lee et al. Journal of Clinical Oncology, 2015, 33, 2712-2713. | 1.6 | 2 |
| 7 | Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy. Clinical Breast Cancer, 2019, 19, e468-e474. | 2.4 | 2 |
| 8 | Synchronous presentation of an Askin tumor and a plasmacytoma in an adult patient. Tumori, 2003, 89, 324-7. | 1.1 | 1 |
| 9 | The Authors Respond. Epidemiology, 2018, 29, e40-e40. | 2.7 | O |
| 10 | Abstract OT-09-06: Phase II neoadjuvant study of GDC-9545 + palbociclib (palbo) vs anastrozole (A) + palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC)., 2021,,. | | 0 |
| 11 | Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial. , 2021, , . | | O |